^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups
Published date:
04/27/2020
Excerpt:
In pts with EGFR/ALK+ tumors and pts with baseline liver mets, OS was comparable in Arms A and C; continued OS benefit in these subgroups was seen in Arm B vs C.
Secondary therapy:
carboplatin + paclitaxel
DOI:
10.1158/1538-7445.AM2020-CT216
Source:
Title:
A non-interventional, single-arm, prospective clinical study for the efficacy and safety of gefitinib combined with bevacizumab and pemetrexed in first-line treatment of stage IV EGFR mutant non-squamous non-small cell lung cancer.
Excerpt:
......
Trial ID:
Source:
Title:
Gefitinib plus pemetrexed combined with bevacizumab or carboplatin in first-line treatment of stage IV EGFR mutant non-squamous non-small cell lung cancer.
Excerpt:
......
Trial ID:
More C2 evidence
Source:
Title:
A randomized open-label phase 3 trial comparing bevacizumab + erlotinib vs erlotinib alone as first line treatment of patients with EGFR mutated advanced non squamous non small cell lung cancer. Studio randomizzato, in aperto, di fase 3, di confronto tra bevacizumab + erlotinib vs erlotinib in monoterapia come trattamento di prima linea di pazienti affetti da carcinoma del polmone non a piccole cellule ad istotipo non squamoso e mutazione attivante di EGFR
Excerpt:
...Activating epidermal growth factor receptor mutation (exon19 deletion or exon 21L858R mutation or other activating/sensitizing mutations, such as exon 21 L861Q,exon 18 G719S, G719A and G719C, exon 20 S768I and V769L). ...
Trial ID:
Source:
Title:
A Multicenter, Randomised, Double blind, Parallel, Phase III Global Study to Assess the Efficacy and Safety of BP01 (Bevacizumab) when compared to Avastin®-EU in Combination with Carboplatin and Paclitaxel during Induction phase and Bevacizumab alone during the Maintenance phase in patients with newly diagnosed or recurrent Stage IIIB/IV Non Squamous (ns) Non-Small Cell Lung Cancer (NSCLC).
Excerpt:
...Subjects with histologic or cytologic diagnosis of nsNSCLC* with negative or unknown sensitizing epidermal growth factor receptor (EGFR) mutation and documented negative or unknown anaplastic lymphoma kinase (ALK) translocation.* mixed cancer types should be classified according to the predominant cell type, if small cell elements are present, subjects must be excluded.4. ...
Trial ID:
Source:
Title:
Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer
Excerpt:
...Prior adjuvant chemotherapy > 1 year ago and prior treatment with an EGFR-TKI for patients with an activating EGFR mutation is allowed....
Source:
Title:
BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)
Excerpt:
...- Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)...
Trial ID:
Source:
Title:
Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
Excerpt:
...An exon 19 deletion mutation or exon 21 L858R mutation in EGFR has been found clinically, with or without EGFR T790M mutation 5....
Source:
Title:
Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer
Excerpt:
...- EGFR mutation(19del/L858R)...
Trial ID:
Source:
Title:
Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer
Excerpt:
...Activating epidermal growth factor receptor mutation (exon19 deletion or exon 21 L858R mutation or other activating/sensitizing mutations, such as exon 21 L861Q, exon 18 G719S, G719A and G719C, exon 20 S768I and V769L)....
Trial ID:
Source:
Title:
Paclitaxel-bevacizumab in Advanced Lung Cancer
Excerpt:
...- Patient with active mutation of EGFR must have had on line of chemotherapy with platinum and one with Tyrosine kinase inhibitor of EGFR....
Trial ID:
Source:
Title:
Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.
Excerpt:
...- Non-squamous non-small cell lung cancer (NSCLC) confirmed by pathology (including histology or cytology); ③ EGFR mutation positive (exon 19 deletion or exon 21 L858R mutation); (4) ≥3 intracranial metastases, asymptomatic brain metastases; (5) Never received antitumor therapy before;...
Trial ID:
Source:
Title:
Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).
Excerpt:
...- Must have EGFR-mutation status (mutated or wild type) confirmed by the central pathologist in Basel...
Trial ID:
Source:
Title:
Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases
Excerpt:
...Patients with histologically or cytologically proven non-epidermoid, non-small cell lung cancer, non-EGFR (Epidermal Growth Factor Receptor)-mutated (or mutation test impracticable)....
Trial ID:
Source:
Title:
Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations
Excerpt:
...An exon 19 deletion mutation or exon 21 L858R mutation has been found in high-sensitivity EGFR mutation tests by PCR using tumor tissue centrally confirmed....
Trial ID:
Source:
Title:
Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease
Excerpt:
...EGFR(epidermal growth factor receptor) mutations, ALK(anaplastic lymphoma kinase) gene fusion, etc.) could be included; 5....
Trial ID:
Source:
Title:
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Excerpt:
...Percentage of Participants With a Complete Response (CR) and Partial Response (PR) (Overall Response Rate)`Percentage of Participants With a Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate)`Progression Free Survival Time`Time to Progressive Disease`Safety and Toxicity Profile of Study Treatments`Duration of Hospitalizations Per Participant`Number of Participants Who Received a Transfusion`Number of Participants Receiving Concomitant Medication`Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - General (FACT-G)`Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - Lung (FACT-L)`Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group- Neurotoxicity (FACT/GOG-Ntx)`Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Pemetrexed`Pharmacokinetics (PK): Elimination Half-life (t1/2) for Pemetrexed`Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Pemetrexed`Pharmacokinetics (PK): Pemetrexed Clearance (CL)`Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Total (Bound and Unbound) Platinum and Unbound Platinum`Pharmacokinetics (PK): Elimination Half-life (t1/2) for Total (Bound and Unbound) Platinum and Unbound Platinum`Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Total (Bound and Unbound) Platinum and Unbound Platinum`Pharmacokinetics (PK): Platinum Clearance (CL) for Total (Bound and Unbound) and Unbound Forms`Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Bevacizumab`Pharmacokinetics (PK): Elimination Half-life (t1/2) for Bevacizumab`Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) Bevacizumab`Pharmacokinetics (PK): Bevacizumab Clearance (CL)`Translational Research: Number of Participants With Epidermal Growth Factor Receptor (EGFR) Mutations`Translational Research: Overall Survival (OS) Based on Nuclear Thyroid Transcription Factor-1 (TTF-1) Expression Regardless of Study Treatment`Translational Research: Overall Survival (OS) Based on Cytoplasmic and Nuclear Thymidylate Synthase (TS) Expression`Translational Research: Overall Survival (OS) Based on Cytoplasmic and Membrane Folate Receptor Alpha (FR-α) Expression...
Trial ID:
Source:
Title:
PD-1 antibody plus chemotherapy versus bevacizumab plus chemotherapy as first-line treatment for patients with PD-L1 negative and EGFR/ALK wild-type advanced or metastatic non-squamous non-small cell lung cancer : an open-label, randomised, multicentre phase 3 trial
Excerpt:
...the research center must be able to provide relevant documentation of the subjects' EGFR mutation and ALK fusion gene status, and all of them must be negative. ...
Trial ID:
Source:
Title:
phase II study evaluating the interest of re-introduction of pemetrexed and platinum (cisplatin or carboplatin) with maintenance by bevacizumab in non squamous non small cell lung cancer of advanced stage. Etude de phase II évaluant l’intérêt de la réintroduction du pemetrexed et du platine (cisplatine ou carboplatine) avec maintien par bevacizumab dans les Cancers BronchoPulmonaires Non à Petites Cellules (CBNPC) non épidermoïdes avancés.
Excerpt:
...Non squamous non small cell lung cancer histologically or cytologically confirmed with no EGFR mutation. ...
Trial ID:
Source:
Title:
Clinical study of gefitinib monotherapy versus gefitinib combined with bevacizumab for advanced NSCLC with positive EGFR 21L858R mutation
Excerpt:
...Histologically or cytologically confirmed non-squamous non-small cell lung cancer, and the use of NGS detection suggested an exon mutation in EGFR 21L858R. ...
Trial ID:
Less C2 evidence
Source:
Title:
First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study
Published date:
08/09/2023
Excerpt:
First-generation EGFR-TKI plus bevacizumab plus chemotherapy was a promising strategy for advanced EGFR-mutated non-squamous NSCLC.
Secondary therapy:
Chemotherapy + EGFR inhibitor
DOI:
https://doi.org/10.1080/07853890.2023.2243967
Source:
Title:
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study
Published date:
02/05/2021
Excerpt:
Advanced non-squamous EGFR-mutated NSCLC patients with gradual progression on EGFR-TKIs were administered bevacizumab while EGFR-TKIs were continued...EGFR-TKIs plus bevacizumab led to a durable prolongation of PFS in non-squamous NSCLC patients with gradual progression on EGFR-TKIs.
Secondary therapy:
EGFR inhibitor
DOI:
10.1097/MD.0000000000023712
Source:
Title:
Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323
Published date:
02/21/2020
Excerpt:
Subgroup analysis showed that the HRs of PFS in female patients, never smokers, and EGFR mutation-positive patients exceeded 1.20 (Figure 2B). Median PFS values assessed by investigators were 7.6 months (95% CI, 5.7–9.8 months) and 7.5 months (95% CI, 4.3–9.6 months) in the docetaxel plus bevacizumab and pemetrexed plus bevacizumab arms, respectively (HR, 1.06; 95% CI, 0.66–1.68).
Secondary therapy:
docetaxel; pemetrexed
DOI:
10.21037/tlcr.2020.03.29
